Abstract

Migraine remains one of the most prevalent and disabling neurological disorders worldwide, affecting millions of individuals. Despite the availability of several therapeutic options, many patients continue to experience inadequate relief, prompting ongoing research into more effective treatments. This paper explores the latest advancements in migraine therapeutics, with a particular focus on novel drug classes, such as CGRP inhibitors and neuromodulation therapies. Additionally, we examine emerging approaches in personalized medicine and digital therapeutics, offering hope for improved outcomes. By highlighting these innovations, we aim to provide a comprehensive overview of the evolving landscape of migraine management, paving the way for more tailored and effective treatment strategies.